Insight journal - Dealtalk

Disappointing trial results end TC-5214 collaboration

Posted on 27 March 2012

Tags: , ,

The deal was announced with fanfare in 2009 with a headline value of $1.24 billion, but was terminated recently as a result of disappointing phase III study results.

AstraZenenca and Targacept announced top line results from their phase III studies investigating efficacy, tolerability and safaty of TC-5214, which was being developed as an adjunct therapy to an antidepressant in patients with major depressive disorder and who did not respond adequately to initial antidepressant treatment. 

Premium content locked

Premium content

The remaining part of this article is Premium content – see below for access options.

CP Insight – Premium content section

This is a premium content section and requires a paid subscription to access.

Please login to read the full article or take a look at the subscribe page for more information on prices.

LOG IN or CONTACT US

Already a subscriber?

Access to this area requires a CP Insight subscription.

Login for complete access

Subscription options

View for more information on pricing

Have a question?

Contact us

Related items:

2011 Deal terminations of the year

Buy the report: Partnering Terms and Agreements in Psychiatry

Buy the report: Partnering Agreements in Depression

View the Partnering scorecard 2009

View the deal in full at Current Partnering (subscription required)

Print Friendly

Leave a Reply

 

bannerpng
bpa14banner300x150jpg
ddp-banner-for-current-partgif
RSS Feed Linked In Twitter

Latest Tweets

ca300x150gif
wildwood-ventures300x150gif
current-partnering-300x150-orphanjpg